| Literature DB >> 19285630 |
Luca Castagna1, Barbara Sarina, Elisabetta Todisco, Massimo Magagnoli, Monica Balzarotti, Stefania Bramanti, Rita Mazza, Antonella Anastasia, Andrea Bacigalupo, Franco Aversa, Davide Soligo, Laura Giordano, Armando Santoro.
Abstract
The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.Entities:
Mesh：
Year: 2009 PMID： 19285630 DOI： 10.1016/j.bbmt.2008.12.506
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN： 1083-8791 Impact factor: 5.742